NFKB1 and Alzheimer disease: Anti-inflammatory drugs aim to mitigate the chronic neuroinflammation seen in AD by targeting pathways like the NF-κB and NLRP3 inflammasome pathways, which are crucial in mediating inflammatory responses in the brain (73).